On February 9th, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly for adult patients with recurrent or advanced endometrial…
On January 27, 2023, the U.S. Food and Drug Administration approved elacestrant for postmenopausal, non-pregnant women and adult men with…
On January 27, 2023, the U.S. Food and Drug Administration approved Pirtobrutinib for adult patients with histologically confirmed relapsed or…
On January 26, 2023, the U.S. Food and Drug Administration approved Pembrolizumab for patients with resectable, stage IB (≥4cm)-IIIA (as…
On January 19, 2023, the U.S. Food and Drug Administration granted accelerated approval to Tucatinib plus Trastuzumab for adult patients…
Janakpurdham, Nepal, April 27, 2022 – The Binaytara Foundation hosted its Fourth International Cancer Congress on April 16, bringing together…
Oncologists Interested in Improving Access to Cancer Care Encouraged to Apply Are you an oncologist who is passionate about educating…
Faculty highlight, Dr. Joseph Rosales!
ASH Review Portland, Highlights from SABCS, and Thoracic Oncology San Diego The Binaytara Foundation is facilitating three conferences with varying…
Meet Chris Nevala-Plagemann, MD, Katie Kerrigan, DO, and Theresa Werner, MD! In this week's faculty highlight, we present Drs. Chris…